KMT2D and pancreatic adenocarcinoma: Alterations such as KMT2D deficiency in chromatin organization have been identified as a favorable prognostic marker in small cell lung cancer, and its potential role to enhance the activity of antitumor treatment in pancreatic adenocarcinoma has been shown [64,65].